Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Total Debt (2019 - 2026)

OptimizeRx's Total Debt history spans 5 years, with the latest figure at $25.7 million for Q4 2025.

  • On a quarterly basis, Total Debt fell 21.76% to $25.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $25.7 million, a 21.76% decrease, with the full-year FY2025 number at $25.7 million, down 21.76% from a year prior.
  • Total Debt hit $25.7 million in Q4 2025 for OptimizeRx, down from $28.1 million in the prior quarter.
  • Over the last five years, Total Debt for OPRX hit a ceiling of $36.2 million in Q4 2023 and a floor of $25.7 million in Q4 2025.
  • Historically, Total Debt has averaged $32.3 million across 3 years, with a median of $32.8 million in 2024.
  • Biggest five-year swings in Total Debt: dropped 9.43% in 2024 and later fell 21.76% in 2025.
  • Tracing OPRX's Total Debt over 3 years: stood at $36.2 million in 2023, then dropped by 9.43% to $32.8 million in 2024, then decreased by 21.76% to $25.7 million in 2025.
  • Business Quant data shows Total Debt for OPRX at $25.7 million in Q4 2025, $28.1 million in Q3 2025, and $28.4 million in Q2 2025.